Table of Contents

• 1.   Market Introduction
  •   1. Objectives of the Study
      2. Market Definition
      3. Market Scope
       3.1 . Years Considered for the Study
       3.2 . Market Covered
      4. Currency
      5. Limitations
      6. Stakeholders
    
• 2.   Research Methodology
  •   1. Research Data
       1.1 . Secondary Data
        1.1.1 . Key Data from Secondary Sources
       1.2 . Primary Data
        1.2.1. Key Data from Primary Sources
      2. Market Size Estimation
      3. Market Breakdown and Data Triangulation
      4. Assumptions for the Study
    
• 3.   Executive Summary
  •   1. Market Outlook
      2. Segment Outlook
      3. Competitive Insights
    
• 4.   Europe Viral Inactivation Market Variables, Trends and Scope

  •   1. Market Lineage Outlook
      2. Penetration and Growth Prospect Mapping
      3. Industry Value Chain Analysis
      4. Cost Analysis Breakdown
      5. Product Overview
      6. Regulatory Framework
       6.1. Reimbursement Framework
       6.2. Standards and Compliances

• 5.   Market Overview
  •   1. Market Dynamics
       1.1. Market Driver Analysis
        1.1.1. Increasing focus of Companies on Brand Protection
        1.1.2. Untapped Opportunities in Emerging Regions
       1.2. Market Restraint Analysis
        1.2.1. High Cost Associated with Implementation of Predictive Analysis
       1.3. Industry Challenges
        1.3.1. Presence of Ambiguous Regulatory Framework
    
• 6.   Europe Viral Inactivation Market Analysis Tools
  •   1. Industry Analysis - Porter’s
       1.1. Supplier Power
       1.2. Buyer Power
       1.3. Substitution Threat
       1.4. Threat from New Entrants
       1.5. Competitive Rivalry
      2. Pestel Analysis
       2.1. Political Landscape
       2.2. Environmental Landscape
       2.3. Social Landscape
       2.4. Product Landscape
       2.5. Legal Landscape
      3. Major Deals And Strategic Alliances Analysis
       3.1. Joint Ventures
       3.2. Mergers and Acquisitions
       3.3. Licensing and Partnership
       3.4. Product Collaborations
       3.5. Strategic Divestments
      4. Market Entry Strategies
      5. Case Studies
    
• 7.   Europe Viral Inactivation Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Kits and Reagents
      2. Services
      3. Accessories

• 8.   Europe Viral Inactivation Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Blood and Blood Products
      2. Cellular and Gene Therapy Products
      3. Stem Cell Products
      4. Tissue and Tissue Products
      5. Vaccines and Therapeutics

• 9.   Europe Viral Inactivation Market, By Method Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Solvent Detergent Method
      2. Pasteurization
      3. Other Viral Inactivation Method

• 10.   Europe Viral Inactivation Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

  •   1. Introduction
      2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
       2.1. Germany
       2.2. U.K
       2.3. France
       2.4. Italy
       2.5. Spain
       2.6. Russia
       2.7. Poland
       2.8. Rest of Europe
      3. Market Size (USD Million) Forecast for Europe 2023-2031

• 11.   Market Share Analysis and Competitive Landscape
  •   1. Europe Landscape - Key Players, Revenue and Presence
      2. Europe Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
      3. Europe Emerging Companies
      4. Europe - Market Share Analysis and Key Regional Players
      5. Europe Key Player - Growth Matrix
    
• 12.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

  •   1. Clean Cells
       1.1. Company Overview
       1.2. Product Portfolio
       1.3. SWOT Analysis
       1.4. Financial Overview
       1.5. Strategic Overview
      2. Charles River Laboratories International, Inc.
       2.1. Company Overview
       2.2. Product Portfolio
       2.3. SWOT Analysis
       2.4. Financial Overview
       2.5. Strategic Overview
      3. Danaher Corporation
       3.1. Company Overview
       3.2. Product Portfolio
       3.3. SWOT Analysis
       3.4. Financial Overview
       3.5. Strategic Overview
      4. Merck KGaA
       4.1. Company Overview
       4.2. Product Portfolio
       4.3. SWOT Analysis
       4.4. Financial Overview
       4.5. Strategic Overview
      5. Parker Hannifin
       5.1. Company Overview
       5.2. Product Portfolio
       5.3. SWOT Analysis
       5.4. Financial Overview
       5.5. Strategic Overview
      6. Rad Source Technologies
       6.1. Company Overview
       6.2. Product Portfolio
       6.3. SWOT Analysis
       6.4. Financial Overview
       6.5. Strategic Overview
      7. Sartorius AG
       7.1. Company Overview
       7.2. Product Portfolio
       7.3. SWOT Analysis
       7.4. Financial Overview
       7.5. Strategic Overview
      8. SGS S.A.
       8.1. Company Overview
       8.2. Product Portfolio
       8.3. SWOT Analysis
       8.4. Financial Overview
       8.5. Strategic Overview
      9. Texcell, Inc.
       9.1. Company Overview
       9.2. Product Portfolio
       9.3. SWOT Analysis
       9.4. Financial Overview
       9.5. Strategic Overview
      10. Viral Inactivated Plasma Systems SA
       10.1. Company Overview
       10.2. Product Portfolio
       10.3. SWOT Analysis
       10.4. Financial Overview
       10.5. Strategic Overview

• 13.   Pre and Post COVID-19 Impact

  •   1. Positive influence on the healthcare industry
      2. The financial disruption of the manufacturing sector
      3. Impact of COVID-19 on emerging companies
      4. Significant mandates in the healthcare regulations initiated by
                administrations
      5. The overall economic slowdown of the developing and developed nations

• 14.   FutureWise SME Key Takeaway Points for Client